Revolutionizing HCC Treatment: A Promising Multimodal Approach With TACE, SBRT, and Immunotherapy
-
Published:2024-05
Issue:3
Volume:14
Page:101321
-
ISSN:0973-6883
-
Container-title:Journal of Clinical and Experimental Hepatology
-
language:en
-
Short-container-title:Journal of Clinical and Experimental Hepatology
Author:
Kumar AshishORCID,
Arora Anil,
Sharma Praveen
Reference13 articles.
1. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial;Chiang;Lancet Gastroenterol Hepatol,2023
2. Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma;J Hepatol,2018
3. 2019 update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the Puri II recommendations;Kumar;J Clin Exp Hepatol,2020
4. The Indian national association for study of the liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the Puri recommendations;Kumar;J Clin Exp Hepatol,2014
5. Hepatocellular carcinoma;Llovet;Nat Rev Dis Prim,2021